New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
15:22 EDTABM, GEF, LDR, PPHM, SURG, TEACompanies reporting After the Market Close on Monday, December 10
Notable companies reporting after the closing bell on Monday include ABM Industries (ABM), Greif (GEF), Landauer (LDR), Peregrine Pharmaceuticals (PPHM), Synergetics (SURG), and Teavana Holdings (TEA).
News For ABM;GEF;LDR;PPHM;SURG;TEA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
07:16 EDTSURGAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
October 17, 2014
14:50 EDTPPHMBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTPPHMSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
October 15, 2014
12:36 EDTPPHMOn The Fly: Midday Wrap
Subscribe for More Information
10:49 EDTPPHMEbola linked names rise again amid broader market sell-off
Subscribe for More Information
10:49 EDTPPHMHigh option volume stocks
High option volume stocks: SNV FCG TXT MDSO PPHM NTRS CCL RGP LLTC SOCL
09:20 EDTPPHMOn The Fly: Pre-market Movers
Subscribe for More Information
08:38 EDTPPHMPeregrine up 21% after saying will examine drug as potential Ebola treatment
08:15 EDTPPHMPeregrine says data support Phosphatidylserine as potential target in Ebola
Peregrine Pharmaceuticals announced the publication of a peer-reviewed manuscript, to appear in the Vaccines and Therapies for Biodefense Agents special edition of the peer-reviewed Journal of Immunology Research in a manuscript titled: "Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions," related to preclinical research demonstrating that the company's lead drug candidate bavituximab, a phosphatidylserine-targeting antibody, exhibits specific and strong binding to Ebola virions and Ebola virus-infected cells in vitro. Cyril Empig, Ph.D., associate research director at Peregrine Pharmaceuticals, said, "Our goal with this work was to continue exploring the potential of bavituximab in the antiviral arena and in this case, specifically in biodefense applications. With the increased focus on Ebola, there is an opportunity to take advantage of the specificity of bavituximab for Ebola virus and develop therapeutics or treatment regimens that could neutralize the virus. In addition, recently reported genomic sequence variations in EBOV suggest that drugs targeting specific viral non-variant proteins or protein sequences are at risk of failure as a result of virus escape mutations...Given these data, we are developing a plan to explore potential applications of bavituximab and PS-targeting antibodies in the treatment of Ebola."
October 14, 2014
16:35 EDTSURGSynergetics reports Q4 EPS 6c, consensus 3c
Subscribe for More Information
October 13, 2014
05:36 EDTABMABM Industries re-initiated with an In-Line at Imperial Capital
Subscribe for More Information
October 8, 2014
10:00 EDTGEFOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ADTRAN (ADTN) upgraded to Buy from Neutral at Goldman... Applied Materials (AMAT) upgraded to Outperform from Underperform at CLSA... Bill Barrett (BBG) upgraded to Neutral from Underperform at Macquarie... CNOOC (CEO) upgraded to Buy from Hold at Jefferies... Calamos (CLMS) upgraded to Market Perform from Underperform at Keefe Bruyette... Calix (CALX) upgraded to Buy from Neutral at Goldman... Cimarex Energy (XEC) upgraded to Outperform from Neutral at Macquarie... Cogent (CCOI) upgraded to Outperform from Market Perform at Raymond James... Coty (COTY) upgraded to Neutral from Sell at B. Riley... Dassault Systemes (DASTY) upgraded to Equal Weight from Underweight at Barclays... EOG Resources (EOG) upgraded to Outperform from Neutral at Macquarie... Glu Mobile (GLUU) upgraded to Buy from Hold at Benchmark Co.... Goldcorp (GG) upgraded to Overweight from Neutral at HSBC... Goodrich Petroleum (GDP) upgraded to Neutral from Underperform at Macquarie... Greif (GEF) upgraded at Wells Fargo... PHH Corp. (PHH) upgraded to Outperform from Market Perform at Keefe Bruyette... Parsley Energy (PE) upgraded to Outperform from Neutral at Macquarie... Rent-A-Center (RCII) upgraded to Buy from Neutral at Northcoast... Royal Gold (RGLD) upgraded to Overweight from Underweight at HSBC... Rush Enterprises (RUSHA) upgraded to Strong Buy at Raymond James... Sanchez Energy (SN) upgraded to Outperform from Neutral at Macquarie... Springleaf (LEAF) upgraded to Outperform from Neutral at Macquarie... TC PipeLines (TCP) upgraded to Neutral from Underweight at JPMorgan... Tesco (TSCDY) upgraded to Neutral from Underweight at HSBC... Vocera (VCRA) upgraded to Outperform at FBR Capital.
07:44 EDTGEFGreif upgraded at Wells Fargo
As noted earlier, Wells Fargo upgraded Greif to Outperform from Market Perform. The firm has become more convinced that the company can turn around its franchise, Wells believes that the company's strategy leaves it positioned for significant earnings and cash flow growth over the next 12-24 months. Target $43.
05:49 EDTGEFGreif upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information
October 6, 2014
08:13 EDTPPHMPeregrine announces presentation of bavituximab data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use